These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 23546290

  • 1. Nobiletin induces inhibitions of Ras activity and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling to suppress cell proliferation in C6 rat glioma cells.
    Aoki K, Yokosuka A, Mimaki Y, Fukunaga K, Yamakuni T.
    Biol Pharm Bull; 2013; 36(4):540-7. PubMed ID: 23546290
    [Abstract] [Full Text] [Related]

  • 2. Activation of protein kinase C betaII/epsilon-c-Jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin.
    Miyata Y, Sato T, Yano M, Ito A.
    Mol Cancer Ther; 2004 Jul; 3(7):839-47. PubMed ID: 15252145
    [Abstract] [Full Text] [Related]

  • 3. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 4. Nobiletin, a Polymethoxylated Flavone, Inhibits Glioma Cell Growth and Migration via Arresting Cell Cycle and Suppressing MAPK and Akt Pathways.
    Lien LM, Wang MJ, Chen RJ, Chiu HC, Wu JL, Shen MY, Chou DS, Sheu JR, Lin KH, Lu WJ.
    Phytother Res; 2016 Feb; 30(2):214-21. PubMed ID: 26560814
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
    Zhang Q, Wei L, Yang H, Yang W, Yang Q, Zhang Z, Wu K, Wu J.
    Cancer Lett; 2016 Feb 01; 371(1):107-16. PubMed ID: 26620707
    [Abstract] [Full Text] [Related]

  • 7. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK, Graab U, Fulda S.
    Cancer Lett; 2013 Sep 01; 337(2):200-9. PubMed ID: 23684925
    [Abstract] [Full Text] [Related]

  • 8. HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways.
    Nakabayashi H, Shimizu K.
    Cancer Sci; 2011 Feb 01; 102(2):393-9. PubMed ID: 21166955
    [Abstract] [Full Text] [Related]

  • 9. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells.
    He S, Dibas A, Yorio T, Prasanna G.
    Exp Biol Med (Maywood); 2007 Mar 01; 232(3):370-84. PubMed ID: 17327470
    [Abstract] [Full Text] [Related]

  • 10. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul 01; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, Schwartz GK.
    Mol Cancer Ther; 2008 Apr 01; 7(4):890-6. PubMed ID: 18413802
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
    Jang K, Kim M, Seo HS, Shin I.
    Oncol Rep; 2010 Sep 01; 24(3):787-93. PubMed ID: 20664988
    [Abstract] [Full Text] [Related]

  • 17. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
    Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J, Bögler O.
    J Transl Med; 2016 Feb 09; 14():46. PubMed ID: 26861698
    [Abstract] [Full Text] [Related]

  • 18. ERK inhibition overcomes acquired resistance to MEK inhibitors.
    Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, Amler LC, Hampton GM, Moffat J, Belvin M, Lackner MR.
    Mol Cancer Ther; 2012 May 09; 11(5):1143-54. PubMed ID: 22402123
    [Abstract] [Full Text] [Related]

  • 19. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
    Kogut MH, Genovese KJ, He H.
    Mol Immunol; 2007 Mar 09; 44(7):1729-36. PubMed ID: 17045653
    [Abstract] [Full Text] [Related]

  • 20. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
    Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A.
    Cell Signal; 2010 Sep 09; 22(9):1369-78. PubMed ID: 20471474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.